Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 9 |
| List of Tables | 6 | 3 |
| List of Figures | 9 | 3 |
| Specialty Pharmaceutical Market- 2011 Yearbook: Introduction | 12 | 1 |
| Scope | 12 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| Specialty Pharmaceutical Market- 2011 Yearbook: HIV Therapeutics Market | 13 | 18 |
| Disease Overview | 13 | 1 |
| Market Overview | 14 | 1 |
| Global HIV Therapeutics Market: Market Characterization | 14 | 1 |
| Market Forecasts | 14 | 2 |
| Annual Cost of Therapy | 16 | 2 |
| Usage Patterns | 18 | 2 |
| Diseased Population | 20 | 1 |
| Treatment Seeking Population | 21 | 1 |
| Diagnosis Population | 22 | 1 |
| Prescription Population | 23 | 1 |
| Geographical Distribution | 24 | 2 |
| HIV Therapeutics Market: Drivers and Restraints | 26 | 1 |
| Market Drivers | 26 | 1 |
| Increase in Awareness Levels of Disease Progression will Lead to an Increase in Treatment Seeking and Diagnosed Populations | 26 | 1 |
| New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake | 27 | 1 |
| Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering the Impact of Generics | 28 | 1 |
| HIV Therapy and Switch to New Drugs | 28 | 1 |
| Market Restraints | 29 | 1 |
| Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions | 29 | 1 |
| Social Stigma Associated with HIV Leads to a Low Rate of Treatment Seeking; Impacting the Overall Customer Base | 30 | 1 |
| Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes | 30 | 1 |
| Specialty Pharmaceutical Market- 2011 Year Book: Age Related Macular Degenerative Disorder | 31 | 10 |
| Disease Overview | 31 | 1 |
| Market Overview | 31 | 1 |
| Age Related Macular Degenerative Disorder: Market Characterization | 32 | 1 |
| Market Forecasts | 32 | 1 |
| Geographical Distribution | 33 | 1 |
| Annual Cost of Therapy | 34 | 1 |
| Usage Patterns | 35 | 1 |
| Diseased Population | 36 | 1 |
| Treatment Seeking Population | 37 | 1 |
| Diagnosis Population | 38 | 1 |
| Prescription Population | 39 | 1 |
| Age Related Macular Degenerative Disorder: Drivers and Restraints | 39 | 1 |
| Market Drivers | 39 | 1 |
| Population Growth | 39 | 1 |
| Diagnosis Rate | 40 | 1 |
| Market Restraints | 40 | 1 |
| Low Treatment Seeking Behavior | 40 | 1 |
| Availability of Alternative Options | 40 | 1 |
| Specialty Pharmaceutical Market- 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD) | 41 | 10 |
| Introduction | 41 | 1 |
| Attention Deficit Hyperactive Disorder: Market Characterization | 41 | 1 |
| Market Forecasts | 41 | 2 |
| Geographical Distribution | 43 | 1 |
| Annual Cost of Therapy | 44 | 1 |
| Usage Patterns | 45 | 1 |
| Diseased Population | 46 | 1 |
| Treatment Seeking Population | 47 | 1 |
| Diagnosis Population | 48 | 1 |
| Prescription Population | 49 | 1 |
| Attention Deficit Hyperactive Disorder Market: Drivers and Restraints | 50 | 1 |
| Market Drivers | 50 | 1 |
| Growing Population | 50 | 1 |
| Prescription Rate | 50 | 1 |
| Market Restraints | 50 | 1 |
| Treatment Seeking Behavior | 50 | 1 |
| Diagnosis Rate | 50 | 1 |
| Availability of Alternative Options | 50 | 1 |
| Specialty Pharmaceutical Market- 2011 Yearbook: Alzheimer s Disease | 51 | 10 |
| Introduction | 51 | 1 |
| Alzheimer s disease: Market Characterization | 51 | 1 |
| Market Forecasts | 51 | 2 |
| Geographical Distribution | 53 | 1 |
| Annual Cost of Therapy | 54 | 1 |
| Usage Patterns | 55 | 1 |
| Diseased Population | 56 | 1 |
| Treatment Seeking Population | 57 | 1 |
| Diagnosis Population | 58 | 1 |
| Prescription Population | 59 | 1 |
| Alzheimer s Disease Market: Drivers and Restraints | 60 | 1 |
| Market Drivers | 60 | 1 |
| Aging population | 60 | 1 |
| Market Restraints | 60 | 1 |
| Treatment Seeking Behavior | 60 | 1 |
| Diagnosis rate | 60 | 1 |
| Pricing | 60 | 1 |
| Specialty Pharmaceutical Market- 2011 Yearbook: Colorectal Cancer | 61 | 10 |
| Introduction | 61 | 1 |
| Colorectal Cancer: Market Characterization | 61 | 1 |
| Market Forecasts | 61 | 2 |
| Geographical Distribution | 63 | 1 |
| Annual Cost of Therapy | 64 | 1 |
| Usage Patterns | 65 | 1 |
| Diseased Population | 66 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosis Population | 68 | 1 |
| Prescription Population | 69 | 1 |
| Colorectal Cancer Market: Drivers and Restraints | 70 | 1 |
| Market Drivers | 70 | 1 |
| Treatment usage patterns | 70 | 1 |
| Annual cost of therapy drivers | 70 | 1 |
| Market Restraints | 70 | 1 |
| Patient Volume | 70 | 1 |
| Specialty Pharmaceutical Market- 2011 Yearbook: Rheumatoid Arthritis | 71 | 10 |
| Introduction | 71 | 1 |
| Rheumatoid Arthritis: Market Characterization | 71 | 1 |
| Market Forecasts | 71 | 2 |
| Annual Cost of Therapy | 73 | 1 |
| Treatment Usage Patterns | 74 | 1 |
| Diseased Population | 75 | 1 |
| Treatment Seeking Population | 76 | 1 |
| Diagnosis Population | 76 | 2 |
| Prescription Population | 78 | 1 |
| Geographical Distribution | 79 | 1 |
| Rheumatoid Arthritis Market: Drivers and Restraints | 80 | 1 |
| Market Drivers | 80 | 1 |
| High incidence and prevalence rate | 80 | 1 |
| Market Restraints | 80 | 1 |
| Low Patient affordability | 80 | 1 |
| Availability of alternative options | 80 | 1 |
| Specialty Pharmaceutical Market- 2011 Yearbook: Epilepsy | 81 | 10 |
| Introduction | 81 | 1 |
| Epilepsy: Market Characterization | 81 | 1 |
| Market Forecasts | 81 | 2 |
| Geographical Distribution | 83 | 1 |
| Annual Cost of Therapy | 84 | 1 |
| Usage Patterns | 85 | 1 |
| Diseased Population | 86 | 1 |
| Treatment Seeking Population | 87 | 1 |
| Diagnosis Population | 88 | 1 |
| Prescription Population | 89 | 1 |
| Epilepsy Market: Drivers and Restraints | 90 | 1 |
| Market Drivers | 90 | 1 |
| Market Restraints | 90 | 1 |
| Low treatment seeking behavior | 90 | 1 |
| Low diagnosis rate and misdiagnosis | 90 | 1 |
| Pricing | 90 | 1 |
| Specialty Pharmaceutical Market- 2011 Yearbook: Glaucoma | 91 | 11 |
| Introduction | 91 | 1 |
| Glaucoma: Market Characterization | 91 | 1 |
| Market Forecasts | 91 | 2 |
| Geographical Distribution | 93 | 1 |
| Annual Cost of Therapy | 94 | 1 |
| Usage Patterns | 95 | 1 |
| Diseased Population | 96 | 1 |
| Treatment Seeking Population | 97 | 1 |
| Diagnosis Population | 98 | 1 |
| Prescription Population | 99 | 1 |
| Glaucoma Market: Drivers and Restraints | 100 | 1 |
| Drivers of the Glaucoma Market | 100 | 1 |
| Eye Diseases Expected to Grow Across Developed Countries | 100 | 1 |
| Improved Diagnostic Equipment to Detect Disease at an Earlier Stage | 100 | 1 |
| Barriers for the Glaucoma Market | 100 | 1 |
| Low Treatment Seeking Rate and Compliance | 100 | 1 |
| Patent Expiries of Major Anti-Glaucoma Products | 101 | 1 |
| Specialty Pharmaceutical Market- 2011Yearbook: Pipeline Analysis | 102 | 40 |
| Specialty Pharmaceutical Pipeline: HIV market | 105 | 1 |
| Molecule Profile for Promising Drugs under Clinical Development: HIV | 106 | 1 |
| Rilpivirine hydrochloride (TMC278) | 106 | 1 |
| Overview | 106 | 1 |
| Efficacy | 106 | 1 |
| Safety | 106 | 1 |
| Clinical Study Details | 106 | 1 |
| Elvitegravir | 107 | 1 |
| Overview | 107 | 1 |
| Efficacy | 107 | 1 |
| Safety | 107 | 1 |
| Clinical Study Details | 107 | 1 |
| Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) | 108 | 1 |
| Overview | 108 | 1 |
| Efficacy | 108 | 1 |
| Safety | 108 | 1 |
| Clinical Study Details | 108 | 1 |
| Racivir | 109 | 1 |
| Overview | 109 | 1 |
| Efficacy | 109 | 1 |
| Safety | 109 | 1 |
| Clinical Study Details | 109 | 1 |
| Apricitabine (ATC) | 110 | 1 |
| Overview | 110 | 1 |
| Efficacy | 110 | 1 |
| Safety | 110 | 1 |
| Clinical Study Details | 110 | 1 |
| Tesamorelin | 111 | 1 |
| Overview | 111 | 1 |
| Efficacy | 111 | 1 |
| Safety | 111 | 1 |
| Clinical Study Details | 111 | 1 |
| Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration | 112 | 1 |
| Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration | 113 | 1 |
| VEGF Trap-Eye | 113 | 1 |
| Overview | 113 | 1 |
| Efficacy | 113 | 1 |
| Safety Profile | 113 | 1 |
| Clinical Study Details | 113 | 1 |
| Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder | 114 | 1 |
| Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder | 115 | 1 |
| ABT-894 (Sofinicline) | 115 | 1 |
| Overview | 115 | 1 |
| Efficacy | 115 | 1 |
| Safety | 115 | 1 |
| Clinical Study Details | 115 | 1 |
| Eltoprazine | 115 | 1 |
| Overview | 115 | 1 |
| Efficacy | 115 | 1 |
| Safety | 115 | 1 |
| Clinical Study Details | 116 | 1 |
| AZD3480 (TC-1734) (Isopronicline) | 116 | 1 |
| Overview | 116 | 1 |
| Efficacy | 116 | 1 |
| Safety | 116 | 1 |
| Clinical Study Details | 116 | 1 |
| Specialty Pharmaceutical Pipeline: Alzheimer s Disease | 117 | 1 |
| Molecular Profile for the Promising Drugs under Clinical Development: Alzheimer s Disease | 118 | 1 |
| Bapineuzumab | 118 | 1 |
| Overview | 118 | 1 |
| Efficacy | 118 | 1 |
| Safety | 118 | 1 |
| Clinical Study Details | 118 | 1 |
| Gammagard | 119 | 1 |
| Overview | 119 | 1 |
| Efficacy | 119 | 1 |
| Safety | 119 | 1 |
| Clinical Study Details | 119 | 1 |
| Dimebon | 120 | 1 |
| Overview | 120 | 1 |
| Efficacy | 120 | 1 |
| Safety | 120 | 1 |
| Clinical Study Details | 120 | 1 |
| Rember (Trx0014) (methylthionium chloride) | 120 | 1 |
| Overview | 120 | 1 |
| Efficacy | 120 | 1 |
| Safety | 121 | 1 |
| Clinical Study Details | 121 | 1 |
| Specialty Pharmaceutical Pipeline: Colorectal Cancer | 122 | 1 |
| Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer | 123 | 1 |
| Aflibercept | 123 | 1 |
| Overview | 123 | 1 |
| Efficacy | 123 | 1 |
| Safety | 123 | 1 |
| Clinical Study Details | 123 | 1 |
| Collaboration Agreements | 124 | 1 |
| Marketing Rights | 124 | 1 |
| Launch Analysis | 124 | 1 |
| Brivanib | 124 | 1 |
| Overview | 124 | 1 |
| Efficacy | 124 | 1 |
| Safety | 125 | 1 |
| Clinical trials | 125 | 1 |
| Collaboration Agreements | 125 | 1 |
| Marketing Rights | 125 | 1 |
| Launch Analysis | 125 | 1 |